Adefovir and Lamivudine for Entecavir Resistance (ALTER Study)
Status:
Completed
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
- Entecavir has been one of the option for treatment of lamivudine resistant chronic
hepatitis B (CHB).
- In case of entecavir resistance, adefovir could be used. However, sequential monotherapy
may result in multidrug resistance.
- It is thought that adefovir and lamivudine combination therapy reduce the risk of
adefovir resistance, thereby continued therapy will lead to suppression of hepatitis B
virus (HBV) DNA to be undetectable in patients with entecavir resistance.
- This study aim to evaluate the efficacy of adefovir and lamivudine combination therapy
in CHB patients with entecavir resistance.